αv-Integrin SMDC Linker Design for Tumor Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug-conjugates (ADCs) face challenges such as low tumor penetration, inefficient internalization, high cost, and complex synthesis, while small molecule drug conjugates (SMDCs) using integrin αvβ3 targeting face issues with ineffective transport, suboptimal internalization, and costly scale-up due to large size and complex synthesis.
Innovation Solution
Development of SMDCs with a simple integrin αvβ3 peptidomimetic targeting piece connected to a large monodisperse polyethylene glycol (PEG) of 20-72 ethylene glycol units, using cleavable linkers and chemotherapies, synthesized through a straightforward, scalable process without multivalent nitrogen moieties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates (ADCs) are used to target cancer cells, then tumor targeting efficiency and chemotherapy release are improved, but production cost and device complexity increase significantly
Solution Approach 1:
The patent replaces expensive, complex antibody-based targeting systems with small molecule integrin αvβ3 ligands that are cheaper to produce and simpler in structure. The small molecule conjugates achieve effective tumor targeting without requiring the complex bioconjugation processes needed for ADCs, thereby reducing production costs and manufacturing complexity while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates simplified copies of the ADC concept by using small molecule integrin ligands that mimic the tumor-targeting function of antibodies. These small molecule conjugates replicate the essential therapeutic mechanism of ADCs (targeted delivery and enzyme-cleavable release) but use simpler, more manufacturable molecular structures that avoid the complexity of antibody production and conjugation
2Reliability
If ADCs are administered via IV infusion, then tumor targeting is achieved, but treatment cost and patient convenience deteriorate due to frequent doctor visits
Solution Approach 1:
The small molecule conjugates are designed to be orally bioavailable, replacing the expensive IV infusion requirement with simple oral administration. This maintains tumor targeting capability while dramatically improving patient convenience by eliminating the need for frequent hospital visits and complex infusion procedures
3Ease of manufacture
If small molecule drug conjugates (SMDCs) are designed with integrin targeting, then production cost is reduced, but internalization efficiency and stability worsen
Solution Approach 1:
The patent optimizes the molecular parameters of the integrin ligands by modifying the spacing between the carboxylic acid and multivalent nitrogen groups. By adjusting this critical distance parameter, the small molecule conjugates achieve both effective integrin binding and efficient cellular internalization, resolving the previous trade-off between manufacturability and biological performance
Solution Approach 2:
The patent creates composite molecular structures that integrate the integrin-targeting ligand, PEG linker, and chemotherapy payload into a single optimized molecule. This composite design ensures stable circulation in blood while maintaining efficient tumor cell internalization and intracellular drug release, overcoming the stability-internalization trade-off
4Reliability
If standard multivalent nitrogen moieties are used in peptidomimetics, then integrin binding is achieved, but synthesis complexity and production cost increase
Solution Approach 1:
The patent modifies the standard peptidomimetic structure by changing the spacing parameter between key functional groups (carboxylic acid and multivalent nitrogen). This parameter optimization maintains strong integrin αvβ3 binding affinity while simplifying the molecular structure for easier and more cost-effective synthesis compared to traditional RGD peptides
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SMDCs achieve high affinity binding to cancer cells, efficient internalization, effective chemotherapy release, and reduced synthesis costs, with tumor shrinkage comparable to chemotherapy alone and a better safety profile.
Implementation Method 1
the chemotherapy is cleaved from the ADC via a specific enzyme (cathepsin B) that is active in these organelles
Data Source
AI summary
A chemical compound and a method for treating cancer in a mammal. The chemical compound is a first Markusch structure of A-L1-PEG1-L2-PEG2-CL-X, a second Markusch structure of A-L1-PEG1-N3, or a third Markusch structure of A-L1-PEG1-OMethyl. A-L1-PEG is a targeting structure configured for targeting av integrins in cancer cells and does not include a standard multivalent nitrogen moiety. A is a structure that includes a standard carboxylic acid moiety. L1 and L2 are linking structures. PEG1 and PEG2 are polyethylene glycol structures having n2 and n4 monomer units, respectively, where n2 is in range of 5-72, n4 is in range of 0-67, and n2+n4 is in range of 20-72. CL is a cleavage linker linked to PEG2. X is a chemotherapy linked to CL. N3 is —N═N═N. In one embodiment, the method uses the first Markusch structure to treat the cancer.